Celecoxib synergizes human pancreatic ductal adenocarcinoma cells to sorafenib-induced growth inhibition

Pancreatology

Volumn 12, Issue 3, 2012, Pages 219-226

  Rosendahl, Ann H ^a   Gundewar, Chinmay ^a   Said, Katarzyna ^a   Karnevi, Emelie ^a   Andersson, Roland ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Celecoxib; Pancreatic cancer; Sorafenib; Synergistic interactions

Indexed keywords

CELECOXIB; CYCLIN DEPENDENT KINASE INHIBITOR 1; SORAFENIB;

APOPTOSIS; CANCER SURVIVAL; CARCINOMA CELL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL VIABILITY; CONFERENCE PAPER; DRUG POTENTIATION; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; WESTERN BLOTTING;

EID: 84862156931     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1016/j.pan.2012.04.005     Document Type: Conference Paper

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in europe in 2008. Eur J Cancer 2010;46:765-81.
3. Burris 3rd HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13. (Pubitemid 27251144)
4. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase iii trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 2007;25:1960-6. (Pubitemid 46972777)
5. Buchholz M, Gress TM. Molecular changes in pancreatic cancer. Expert Rev Anticancer Ther 2009;9:1487-97.
6. Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-17.
7. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-k-ras genes. Cell 1988;53:549-54.
8. Smit VT, Boot AJ, Smits AM, Fleuren GJ, Cornelisse CJ, Bos JL. Kras codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 1988;16:7773-82.
9. Biankin AV, Kench JG, Morey AL, Lee CS, Biankin SA, Head DR, et al. Overexpression of p21(waf1/cip1) is an early event in the development of pancreatic intraepithelial neoplasia. Cancer Res 2001;61:8830-7. (Pubitemid 34013897)
10. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. Bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the raf/mek/ erk pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109. (Pubitemid 39331023)
11. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al. Phase ii placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-12. (Pubitemid 46630627)
12. Kane RC, Farrell AT, Madabushi R, Booth B, Chattopadhyay S, Sridhara R, et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 2009;14:95-100.
13. Dasmahapatra G, Yerram N, Dai Y, Dent P, Grant S. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve mcl-1 and p21cip1 down-regulation. Clin Cancer Res 2007;13: 4280-90. (Pubitemid 47108172)
14. Park MA, Reinehr R, Haussinger D, Voelkel-Johnson C, Ogretmen B, Yacoub A, et al. Sorafenib activates cd95 and promotes autophagy and cell death via src family kinases in gastrointestinal tumor cells. Mol Cancer Ther 2010;9: 2220-31.
15. Rausch V, Liu L, Kallifatidis G, Baumann B, Mattern J, Gladkich J, et al. Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res 2010;70:5004-13.
16. Matsubayashi H, Infante JR, Winter J, Klein AP, Schulick R, Hruban R, et al. Tumor cox-2 expression and prognosis of patients with resectable pancreatic cancer. Cancer Biol Ther 2007;6:1569-75. (Pubitemid 351590328)
17. Merati K, said Siadaty M, Andea A, Sarkar F, Ben-Josef E, Mohammad R, et al. Expression of inflammatory modulator cox-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters. Am J Clin Oncol 2001;24:447-52. (Pubitemid 32959100)
18. Juuti A, Louhimo J, Nordling S, Ristimaki A, Haglund C. Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol 2006;59:382-6.
19. Prescott SM, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 2000;1470:M69-78. (Pubitemid 30155608)
20. Rao R, Redha R, Macias-Perez I, Su Y, Hao C, Zent R, et al. Prostaglandin e2-ep4 receptor promotes endothelial cell migration via erk activation and angiogenesis in vivo. J Biol Chem 2007;282:16959-68. (Pubitemid 47093223)
21. El-Rayes BF, Ali S, Sarkar FH, Philip PA. Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines. Mol Cancer Ther 2004;3:1421-6. (Pubitemid 39562587)
22. Ali S, El-Rayes BF, Sarkar FH, Philip PA. Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Mol Cancer Ther 2005;4:1943-51. (Pubitemid 43056977)
23. Zhao L, Wientjes MG, Au JL. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 2004;10:7994-8004. (Pubitemid 39587541)
24. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, et al. Phase i clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor receptor inhibitor bay 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-72. (Pubitemid 46202316)
25. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. Cox-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective cox-2 inhibitor celecoxib. FASEB J 2001;15:2742-4.
26. Levitt RJ, Buckley J, Blouin MJ, Schaub B, Triche TJ, Pollak M. Growth inhibition of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression. Biochem Biophys Res Commun 2004;316:421-8. (Pubitemid 38338610)
27. Ali S, Banerjee S, Schaffert JM, El-Rayes BF, Philip PA, Sarkar FH. Concurrent inhibition of nf-kappab, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer. J Cell Biochem 2010;110:171-81.
28. Nguyen TK, Jordan N, Friedberg J, Fisher RI, Dent P, Grant S. Inhibition of mek/ erk1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis. Leuk Res 2010;34:379-86.
29. Inoue H, Hwang SH, Wecksler AT, Hammock BD, Weiss RH. Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy. Cancer Biol Ther 2011;12(9):827-36.
30. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment. Trends Cell Biol 2003;13:65-70. (Pubitemid 36135887)
31. Suzuki A, Tsutomi Y, Akahane K, Araki T, Miura M. Resistance to fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21waf1 and iap gene family ilp. Oncogene 1998;17:931-9. (Pubitemid 28425403)
32. Suzuki A, Tsutomi Y, Yamamoto N, Shibutani T, Akahane K. Mitochondrial regulation of cell death: mitochondria are essential for procaspase 3-p21 complex formation to resist fas-mediated cell death. Mol Cell Biol 1999;19: 3842-7. (Pubitemid 29193843)
33. Ding H, Han C, Guo D, Wang D, Duan W, Chen CS, et al. Sensitivity to the noncox inhibiting celecoxib derivative, osu03012, is p21(waf1/cip1) dependent. Int J Cancer 2008;123:2931-8.